Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes (COCONUT)

NCT04307797 PHASE4 COMPLETED

The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into participants with type 2 diabetes (T2DM). Overall, the aim of the study is to further the investigator's understanding on the role these endogenous substances have on normal cardiac physiology, myocardial energetics and myocardial glucose uptake through a series of PET and MRI imaging studies

Details

Lead sponsor	Cambridge University Hospitals NHS Foundation Trust
Phase	PHASE4
Status	COMPLETED
Enrolment	10
Start date	Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Type 2 Diabetes
• Obesity

Interventions

• 0.9% Sodium-chloride
• Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
• Glucagon 12.5ng/kg/min and 0.9% saline
• 0.9% Sodium-chloride
• Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min
• Glucagon 12.5ng/kg/min

Countries

United Kingdom